Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004845 · ClinicalTrials.gov registry record · Phase 2
A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)
A Phase 2 study of Alzheimer Disease, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00004845 is a Phase 2 study of Alzheimer Disease that has completed, run by National Institute on Aging (NIA). The trial reports 20 study locations across 9 states.
The verdict
NCT00004845, a Phase 2 study of Alzheimer Disease, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured by ADAScog.
Conditions Studied
Interventions
- DRUG Naproxen
- DRUG Rofecoxib
Study Locations (20)
Florida
- Baumel-Eisner Neuromedical Institute, Boca Raton - Boca Raton
- Baumel-Eisner Ft Lauderdale - Fort Lauderdale
- Mayo Clinic Jacksonville - Jacksonville
- Wein Center - Miami Beach
- Baumel-Eisner Neuromedical Institute, MiamiBeach - Miami Beach
- University of South Florida - Tampa
- Premiere Research Institute - West Palm Beach
California
- University of California Irvine Institute for Brain Aging and Dementia - Irvine
- University of California, San Diego - La Jolla
- University of Southern California - Los Angeles
- University of California, Los Angeles - Los Angeles
- University of California, Davis - Martinez
Arizona
- Barrow Neurological Group - Phoenix
- University of Arizona, Tucson - Tucson
Connecticut
- Yale University, School of Medicine - New Haven
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Georgia
- Emory University - Atlanta
Illinois
- Rush Presbyterian St. Luke's Medical Center - Chicago
Indiana
- Indiana University Medical Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2001-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004845
The ClinicalTrials.gov registry entry for NCT00004845 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Naproxen is the first listed.
NCT00004845 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00004845 about?
NCT00004845 is a clinical study titled "A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)". The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured by ADAScog.
What is the current status of trial NCT00004845?
This trial is currently completed. It is a Phase 2 study. Estimated completion is 2001-12.
What conditions does trial NCT00004845 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT00004845?
The interventions under investigation include: Naproxen (DRUG), Rofecoxib (DRUG).
Who is sponsoring clinical trial NCT00004845?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004845 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.